Get the Stockscreener App
220.81
2.10%
4.55
After Hours:
220.01
-0.80
-0.36%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $220.81, with a volume of 5.26M.
It is up +2.10% in the last 24 hours and up +6.83% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$216.26
Open:
$219.1
24h Volume:
5.26M
Relative Volume:
0.97
Market Cap:
$390.07B
Revenue:
$58.33B
Net Income/Loss:
$3.73B
P/E Ratio:
105.15
EPS:
2.1
Net Cash Flow:
$18.24B
1W Performance:
+4.33%
1M Performance:
+6.83%
6M Performance:
+2.96%
1Y Performance:
+14.14%
1-Day Range:
$217.30
$221.55
1-Week Range:
$214.31
$221.76
52-Week Range:
$163.81
$221.76
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
220.81 | 382.04B | 58.33B | 3.73B | 18.24B | 2.10 |
|
LLY
Lilly Eli Co
|
760.13 | 685.53B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
177.20 | 424.98B | 90.62B | 22.66B | 18.18B | 9.35 |
|
NVS
Novartis Ag Adr
|
122.47 | 237.68B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
81.14 | 202.55B | 63.43B | 16.42B | 14.72B | 6.49 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie (ABBV) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Records on Cerevel Trades Before AbbVie Sale May Be Released (1) - Bloomberg Law News
Aug Catalysts: Can AbbVie Inc sustain its profitabilityWeekly Trade Review & Daily Profit Maximizing Trade Tips - خودرو بانک
AbbVie’s SWOT analysis: biopharmaceutical giant faces policy risks amid strong growth - Investing.com
Oruka jumps as lead drug outperforms AbbVie’s Skyrizi in early-stage trial - Seeking Alpha
This Workday Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Berenberg Upgrades AbbVie (ABBV) - Nasdaq
Berenberg Upgrades AbbVie to Buy From Hold, Adjusts Price Target to $270 From $170 - MarketScreener
AbbVie, Novo get Berenberg boost while Lilly, Merck face downgrades - Investing.com
Abbvie, Kroger, Workday - TradingView
September 16, 2025 - Pharmaceutical Executive
AbbVie: Best Time To Sell In 5 Years (Rating Downgrade) (NYSE:ABBV) - Seeking Alpha
Guggenheim Reiterates a Buy Rating on AbbVie (ABBV), Sets a PT of $227 - Yahoo Finance
Is ABBV Stock a Buy, Hold, or Sell After Its Almost 23% Rise YTD? - sharewise.com
AbbVie (ABBV)’s Dividend Track Record: How It Became a Leader in Consistent Dividends - Yahoo Finance
With big pharma circling psychedelics, the next breakthrough may not come from tripping at all - microdose.buzz
JPMorgan Adjusts Price Target on AbbVie to $235 From $200, Maintains Overweight Rating - MarketScreener
AbbVie Settles Rinvoq Litigation, Blocks Generics Until 2037 - Law360
AbbVie's VRAYLAR® Gains Public Reimbursement In Alberta For Schizophrenia Treatment - Nasdaq
AbbVie loses appeal over Mississippi 340B state law - Endpoints News
11 Newly Overvalued Stocks for the Week - Morningstar
AbbVie Says Vraylar Antipsychotic Medication Now Listed on Alberta's Health Drug Formulary - MarketScreener
Deutsche Bank Adjusts Price Target on AbbVie to $204 From $173 - MarketScreener
AbbVie's VRAYLAR® (cariprazine) Now Publicly Reimbursed in Alberta - Yahoo Finance
Cantor Fitzgerald Adjusts AbbVie Price Target to $245 From $215, Maintains Overweight Rating - MarketScreener
Deutsche Bank Adjusts AbbVie Price Target to $204 From $173, Maintains Hold Rating - MarketScreener
AbbVie loses bid to block 340B law in Mississippi - pharmaphorum
What would a sea change in drug advertising mean for big-spending AbbVie? - Crain's Chicago Business
Barrett's Esophagus Strategic Business Report 2025-2030 Featuring 34 Companies - GlobeNewswire Inc.
Capital Market Strategies LLC Sells 1,975 Shares of AbbVie Inc. $ABBV - MarketBeat
Teamwork Financial Advisors LLC Has $595,000 Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Bought by First Financial Bank Trust Division - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by Wesbanco Bank Inc. - MarketBeat
LVM Capital Management Ltd. MI Has $31.06 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
Jacobs & Co. CA Buys 1,211 Shares of AbbVie Inc. $ABBV - MarketBeat
Good Steward Wealth Advisors LLC Sells 1,932 Shares of AbbVie Inc. $ABBV - MarketBeat
Neville Rodie & Shaw Inc. Trims Stake in AbbVie Inc. $ABBV - MarketBeat
Park National Corp OH Has $21.83 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Belpointe Asset Management LLC Sells 4,903 Shares of AbbVie Inc. $ABBV - MarketBeat
Intech Investment Management LLC Sells 90,154 Shares of AbbVie Inc. $ABBV - MarketBeat
Dynamic Technology Lab Private Ltd Invests $383,000 in AbbVie Inc. $ABBV - MarketBeat
Acadian Asset Management LLC Acquires 7,640 Shares of AbbVie Inc. $ABBV - MarketBeat
Fortis Capital Advisors LLC Has $993,000 Stock Position in AbbVie Inc. $ABBV - MarketBeat
Blue Rock Wealth Management LLC Buys New Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by Thurston Springer Miller Herd & Titak Inc. - MarketBeat
TruWealth Advisors LLC Has $26.46 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
McAdam LLC Reduces Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Ransom Advisory Ltd Acquires Shares of 13,215 AbbVie Inc. $ABBV - MarketBeat
Integrity Alliance LLC. Purchases 20,680 Shares of AbbVie Inc. $ABBV - MarketBeat
IFM Investors Pty Ltd Purchases 3,741 Shares of AbbVie Inc. $ABBV - MarketBeat
Glenview Trust co Boosts Holdings in AbbVie Inc. $ABBV - MarketBeat
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):